Janux Therapeutics, Inc.
JANX
$28.80
$1.937.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -82.56% | 741.72% | -38.87% | -13.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -82.56% | 741.72% | -38.87% | -13.50% |
| Cost of Revenue | 69.97% | 56.53% | -0.17% | -11.31% | -20.69% |
| Gross Profit | -112.74% | -93.87% | 56.72% | 7.23% | 22.31% |
| SG&A Expenses | 29.24% | 174.42% | 13.66% | 13.60% | 11.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.05% | 97.93% | 4.19% | -4.10% | -11.90% |
| Operating Income | -79.85% | -126.66% | 33.38% | 0.59% | 11.66% |
| Income Before Tax | -71.93% | -142.56% | 65.96% | 15.46% | 26.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.93% | -142.56% | 65.96% | 15.46% | 26.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.93% | -142.56% | 65.96% | 15.46% | 26.81% |
| EBIT | -79.85% | -126.66% | 33.38% | 0.59% | 11.66% |
| EBITDA | -82.69% | -130.73% | 34.33% | 1.00% | 12.64% |
| EPS Basic | -41.21% | -102.92% | 73.86% | 28.01% | 34.79% |
| Normalized Basic EPS | -41.23% | -102.91% | 73.85% | 28.01% | 34.82% |
| EPS Diluted | -41.21% | -102.92% | 73.86% | 28.01% | 34.79% |
| Normalized Diluted EPS | -41.23% | -102.91% | 73.85% | 28.01% | 34.82% |
| Average Basic Shares Outstanding | 21.74% | 19.52% | 30.15% | 17.44% | 12.26% |
| Average Diluted Shares Outstanding | 21.74% | 19.52% | 30.15% | 17.44% | 12.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
